Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000721535 | SCV000705066 | uncertain significance | not provided | 2017-01-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000623845 | SCV000741932 | uncertain significance | Inborn genetic diseases | 2016-11-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000818782 | SCV000959414 | uncertain significance | RYR1-related disorder | 2022-10-21 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 148 of the RYR1 protein (p.Thr148Ile). This variant is present in population databases (rs151325948, gnomAD 0.2%). This variant has not been reported in the literature in individuals affected with RYR1-related conditions. ClinVar contains an entry for this variant (Variation ID: 499535). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on RYR1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV000721535 | SCV001776591 | uncertain significance | not provided | 2024-07-24 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 33767344, 32236737) |
Fulgent Genetics, |
RCV002497264 | SCV002814322 | uncertain significance | Central core myopathy; Malignant hyperthermia, susceptibility to, 1; Congenital multicore myopathy with external ophthalmoplegia; Congenital myopathy with fiber type disproportion; King Denborough syndrome | 2022-02-10 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000721535 | SCV003810547 | uncertain significance | not provided | 2023-04-10 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV003514380 | SCV004357262 | likely benign | Malignant hyperthermia, susceptibility to, 1 | 2022-08-04 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000721535 | SCV005194577 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV000818782 | SCV000852621 | likely benign | RYR1-related disorder | 2023-06-16 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |